American College of Cardiology and Medscape

• HDL-C Levels' Role in Cardioprotection: 5 Things to Know Targeting HDL-C function can be an effective strategy to understand mechanisms related to CV protection, which in turn can lead to the development of newer therapies to prevent CVD.
  American College of Cardiology & Medscape , December 11, 2023
• How Low Should You Go? Is Very Low LDL-C Safe? Drs Connie Newman and Seth Martin highlight the evidence supporting the safety of very low LDL-C levels, and how maintaining low levels protects against CV events such as MI and stroke.
  American College of Cardiology & Medscape , December 01, 2023
  17
• Diagnosing Cardiac Amyloidosis: 5 Things to Know Dr Taylor Lebeis highlights the key aspects of a diagnostic workup for cardiac amyloidosis.
  American College of Cardiology & Medscape , November 20, 2023
• Managing Dyslipidemia in 50-Year-Old Man With Hypothyroidism A 50-year-old man with primary hypothyroidism is referred by his primary care physician to a cardiologist for evaluation of high low-density lipoprotein cholesterol. How would you manage his case?
  American College of Cardiology & Medscape , October 31, 2023
  3
• The Ever-Evolving Landscape of Lipid-Lowering Therapies   Drs Pam Taub and Steve Nissen discuss the current state of lipid management and what is on the horizon, thanks to the impact of highly anticipated clinical trial outcomes.
  American College of Cardiology & Medscape , October 20, 2023
  4
• Surveilling Heart Rejection: A Guide to Noninvasive Methods   Dr Michelle Kittleson shares noninvasive monitoring strategies for heart transplant rejection.
  American College of Cardiology & Medscape , October 05, 2023
• Upping the Pace in Acute Decompensated Heart Failure Therapy   April Stempien-Otero, MD, discusses new approaches in uptitration for GDMT and progressive physical rehabilitation in acute decompensated heart failure treatment.
  American College of Cardiology & Medscape , August 22, 2023
  2
• Key Steps to Optimizing GDMT in Heart Failure   Dr Biykem Bozkurt outlines strategies for achieving guideline-directed medical therapy optimization.
  American College of Cardiology & Medscape , August 01, 2023
  1
• Best Practices for SGLT2 Inhibitors in HFpEF Treatment   Drs Matthew Konerman and Sarah Adie share expert insights on SGLT2 inhibitor use in managing heart failure with preserved ejection fraction.
  American College of Cardiology & Medscape , July 17, 2023
• Measuring Atherogenic Lipids: Does One Equation Rise Above?   Drs Pam Taub and Seth Martin explore the myriad of options to measure atherogenic lipids and the ongoing debate of whether an optimal assessment exists in lipid and CVD risk management.
  American College of Cardiology & Medscape , July 14, 2023
  12
• Key Takeaways From the AHA Statement on CAM in HF Drs Marty Tam and Christopher Giuliano discuss safety concerns and the appropriatness of adding complementary therapies to guideline-directed treatments.
  American College of Cardiology & Medscape , May 16, 2023
  4
• Targeted Strategies in Lipid-Lowering Therapy   Drs Seth Baum, Matthew Budoff, and Jay Shubrook discuss the current treatment landscape of lipid-lowering therapies and what we can expect to see next from the pipeline.
  American College of Cardiology & Medscape , May 12, 2023
• Practical Tips for Heart Failure Prevention   Dr Payal Kohli discusses key strategies for heart failure prevention.
  American College of Cardiology & Medscape , April 12, 2023
• What About Lp(a)? To Test or Not to Test   Drs Seth Baum and Matthew Budoff discuss the importance of and considerations for Lp(a) screening to optimize patient care.
  American College of Cardiology & Medscape , January 05, 2023
  13
• CRT in HFrEF Management: Updates Plus 'What's Next?'   Drs Chung and Bhatia discuss the evolution of cardiac resynchronization therapy, guideline recommendations, and emerging technologies.
  American College of Cardiology & Medscape , December 08, 2022
  2
• Heart Transplantation Outcomes After the New OPTN Policy Drs Chang and Colvin review the 2018 heart allocation policy and its effects on wait-list and posttransplantion outcomes, plus future policy updates.
  American College of Cardiology & Medscape , October 11, 2022
• State of the Art in NAFLD/NASH Identification and Management   Drs Seth Baum and Jay Shubrook explore the highly anticipated Clinical Care Pathway for the screening, diagnosis, and treatment of NAFLD/NASH.
  American College of Cardiology & Medscape , October 03, 2022
• Stepping Up to Achieve Health Equity in Heart Failure   Drs Alanna Morris and Khadijah Breathett discuss strategies for reducing healthcare disparities among patients with heart failure.
  American College of Cardiology & Medscape , September 07, 2022
• What's New on the Lipid Management Landscape?   Drs Pam Taub and Steve Nissen discuss the current state of lipid management and what is on the horizon, thanks to the impact of highly anticipated new therapies to join the armamentarium.
  American College of Cardiology & Medscape , August 01, 2022
  19
• SGLT2 Inhibitors vs GLP-1 Agonists: Go It Alone or Join Forces?   Should SGLT2 Inhibitors and GLP-1 agonists be prescribed singly or jointly? Drs Matthew Budoff and Yehuda Handelsman discuss the options.
  American College of Cardiology & Medscape , June 22, 2022